ChitogenX Inc. (CHGX.CN)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.87 Million CAD | -30.36% |
| 2022 | 5.56 Million CAD | -2.56% |
| 2021 | 5.71 Million CAD | 23.73% |
| 2020 | 4.61 Million CAD | 73.17% |
| 2019 | 2.66 Million CAD | 130.62% |
| 2018 | 1.15 Million CAD | 3.25% |
| 2017 | 1.11 Million CAD | 27.2% |
| 2016 | 879.85 Thousand CAD | 266.6% |
| 2015 | 240 Thousand CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 4.12 Million CAD | 2.36% |
| 2024 Q1 | 4.03 Million CAD | 4.08% |
| 2023 Q1 | 6.99 Million CAD | 25.65% |
| 2023 FY | 3.87 Million CAD | -30.36% |
| 2023 Q2 | 3.65 Million CAD | -47.78% |
| 2023 Q4 | 3.87 Million CAD | 10.56% |
| 2023 Q3 | 3.5 Million CAD | -4.0% |
| 2022 Q2 | 5.86 Million CAD | 3.26% |
| 2022 Q4 | 5.56 Million CAD | -8.18% |
| 2022 FY | 5.56 Million CAD | -2.56% |
| 2022 Q1 | 5.68 Million CAD | -0.51% |
| 2022 Q3 | 6.06 Million CAD | 3.31% |
| 2021 Q1 | 4.72 Million CAD | 2.38% |
| 2021 FY | 5.71 Million CAD | 23.73% |
| 2021 Q4 | 5.71 Million CAD | 22.9% |
| 2021 Q3 | 4.64 Million CAD | 2.83% |
| 2021 Q2 | 4.51 Million CAD | -4.38% |
| 2020 Q3 | 3.28 Million CAD | -0.45% |
| 2020 Q1 | 3.14 Million CAD | 18.09% |
| 2020 Q2 | 3.29 Million CAD | 4.77% |
| 2020 Q4 | 4.61 Million CAD | 40.62% |
| 2020 FY | 4.61 Million CAD | 73.17% |
| 2019 Q1 | 1.11 Million CAD | -3.77% |
| 2019 Q3 | 1.96 Million CAD | 32.68% |
| 2019 Q4 | 2.66 Million CAD | 35.35% |
| 2019 Q2 | 1.48 Million CAD | 33.45% |
| 2019 FY | 2.66 Million CAD | 130.62% |
| 2018 Q3 | 816.4 Thousand CAD | 3.66% |
| 2018 Q1 | 1.15 Million CAD | 2.88% |
| 2018 FY | 1.15 Million CAD | 3.25% |
| 2018 Q4 | 1.15 Million CAD | 41.54% |
| 2018 Q2 | 787.58 Thousand CAD | -31.6% |
| 2017 Q2 | 782.43 Thousand CAD | 46.89% |
| 2017 Q1 | 532.68 Thousand CAD | -39.46% |
| 2017 FY | 1.11 Million CAD | 27.2% |
| 2017 Q4 | 1.11 Million CAD | 3.24% |
| 2017 Q3 | 1.08 Million CAD | 38.55% |
| 2016 Q4 | 879.85 Thousand CAD | 58.77% |
| 2016 Q3 | 554.15 Thousand CAD | 4.13% |
| 2016 Q1 | 260 Thousand CAD | 8.33% |
| 2016 FY | 879.85 Thousand CAD | 266.6% |
| 2016 Q2 | 532.15 Thousand CAD | 104.67% |
| 2015 Q4 | 240 Thousand CAD | 0.0% |
| 2015 FY | 240 Thousand CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | - CAD | -Infinity% |
| Asep Medical Holdings Inc | 20 Thousand CAD | -19275.0% |
| BetterLife Pharma Inc. | 245.23 Thousand CAD | -1480.123% |
| BioVaxys Technology Corp. | - CAD | -Infinity% |
| Rapid Dose Therapeutics Corp. | 2.45 Million CAD | -57.927% |
| Defence Therapeutics Inc. | 1.74 Million CAD | -121.879% |
| Entheon Biomedical Corp. | - CAD | -Infinity% |
| Gemina Laboratories Ltd. | 285.32 Thousand CAD | -1258.096% |
| Glow Lifetech Corp. | 116.18 Thousand CAD | -3235.227% |
| Lexston Life Sciences Corp. | - CAD | -Infinity% |
| Pharmala Biotech Holdings Inc. | 253.53 Thousand CAD | -1428.377% |
| Doseology Sciences Inc. | - CAD | -Infinity% |
| MYND Life Sciences Inc. | 3 Million CAD | -29.167% |
| Nova Mentis Life Science Corp. | - CAD | -Infinity% |
| PharmaTher Holdings Ltd. | - CAD | -Infinity% |
| PreveCeutical Medical Inc. | 3.83 Million CAD | -1.065% |
| Telescope Innovations Corp. | - CAD | -Infinity% |